The most aggressive forms of prostate cancer include small cell carcinoma of the prostate, ductal adenocarcinoma, and poorly differentiated tumors presenting with a very high Gleason score of 9 or 10, or a Grade Group 5 classification. These rare and highly aggressive variants tend to grow rapidly, invade local surrounding tissues early, and metastasize to distant organs such as the bones and liver much sooner than typical acinar adenocarcinomas. They often require intensive, multi-modal treatment regimens combining aggressive systemic chemotherapy, specialized radiation protocols, and novel targeted agents rather than standard localized management strategies.